ArticleBMC endocrine disorders2026
Autoimmune thyroid disease-is high prolactin a risk factor?
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn addition to its classic effect of lactation, prolactin (PRL) has begun to attract attention for its non-classic effects, particularly on the immune system.
objectiveThis study aimed to compare the prevalence of autoimmune thyroid disease (AITD), thyroid autoantibodies, and thyroid function tests (TFTs) in patients with hyperprolactinemia (HPRL) of at least 25 ng/ml and in healthy controls with PRL of less than 25 ng/ml. We conducted a retrospective case-control study at a single tertiary referral center. All study participants underwent measurement of antibodies to thyroglobulin (anti-Tg), thyroid peroxidase (anti-TPO), TSH, and fT4 levels, as well as ultrasonographic thyroid pattern assessment.
resultsThe AITD rate was found to be 33.5% in those with PRL ≥ 25. In the healthy control group, this rate was 23.5%, and this difference was statistically significant (p = 0.006). Among those with PRL ≥ 25, anti-TPO and anti-Tg levels, as well as TSH levels, were significantly higher, and sT4 levels were significantly lower compared to the control group (p < 0.001). There was a positive relationship between PRL levels and TSH, anti-Tg, and anti-TPO levels, while there was a negative relationship with sT4 levels, all of which were statistically significant but relatively weak. The ROC analysis revealed that the PRL level was 21.77 ng/mL for detecting anti-TPO positivity and anti-Tg positivity; the cut-off value was determined to be 21.92 ng/mL.
conclusionsThere is an increase in the frequency of AITD and thyroid autoantibodies in HPRL patients. We can conclude that exceeding the PRL threshold value increases the risk. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.